# SPECIALTY GUIDELINE MANAGEMENT

# **OCREVUS** (ocrelizumab)

### **POLICY**

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### **FDA-Approved Indications**

- A. Ocrevus is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
- B. Ocrevus is indicated for the treatment of primary progressive MS, in adults.

All other indications are considered experimental/investigational and not medically necessary.

### II. PRESCRIBER SPECIALTIES

This medication must be prescribed by or in consultation with a neurologist.

#### III. CRITERIA FOR INITIAL APPROVAL

## A. Relapsing Forms of Multiple Sclerosis

Authorization of 12 months may be granted to members who have been diagnosed with a relapsing form of multiple sclerosis (including relapsing-remitting and secondary progressive disease for those who continue to experience relapse).

### **B.** Clinically Isolated Syndrome

Authorization of 12 months may be granted to members for the treatment of clinically isolated syndrome of multiple sclerosis.

### C. Primary Progressive Multiple Sclerosis

Authorization of 12 months may be granted to members for the treatment of primary progressive multiple sclerosis.

## IV. CONTINUATION OF THERAPY

For all indications: Authorization of 12 months may be granted for members who are experiencing disease stability or improvement while receiving Ocrevus.

#### V. OTHER

Ocrevus 1707-A SGM P2023.docx

© 2023 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



Reference number(s) 1707-A

- A. Members will not use Ocrevus concomitantly with other disease modifying multiple sclerosis agents (Note: Ampyra and Nuedexta are not disease modifying).
- B. Authorization may be granted for pediatric members less than 18 years of age when benefits outweigh risks.

### VI. REFERENCES

- 1. Ocrevus [package insert]. South San Francisco, CA: Genentech, Inc.; March 2023.
- 2. Clinical Consult: CVS Caremark Clinical Program Review. Focus on Multiple Sclerosis Clinical Programs. June 22, 2017.

Ocrevus 1707-A SGM P2023.docx

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2023 CVS Caremark. All rights reserved.





This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of